Stem Cell IV Therapy
This whole-body approach delivers MSCs intravenously, where they provide systemic support through cellular communication pathways.
Research focus: Systemic wellness, immune modulation, comprehensive supportive therapy
Wharton's Jelly MSCs
Research indicates these mesenchymal stem cells support tissue repair processes through anti-inflammatory and regenerative mechanisms.
Research focus: Joint support, cellular health, systemic vitality
Lyophilized Subcutaneous Implant
This freeze-dried cellular matrix implant delivers gradual release of bioactive factors following subcutaneous placement.
Research focus: Sustained support, foundation therapy applications
Exosomes
Extracellular vesicles facilitate intercellular communication and support regenerative signaling pathways.
Research focus: Cellular optimization, skin health, signaling support
Platelet Rich Plasma (PRP)
Concentrated growth factors derived from the patient's own blood support tissue repair processes.
Research focus: Joint support, soft tissue healing, hair restoration
Ozone Therapy
An oxygen-based therapy supports circulation and immune modulation.
Research focus: Circulation support, immune modulation, preconditioning
Orthopedics & Sports Medicine
Research explores how Stem Cell IV Therapy supports joint and tendon health.
Learn MoreHealthy Aging & Wellness
Research examines systemic MSC support for age-related health maintenance.
Learn MoreSports Injury & Recovery
Research explores Stem Cell IV Therapy for recovery support in active individuals.
Learn MoreMetabolic Health
Research explores Stem Cell IV Therapy for metabolic support applications.
Learn MoreUnderstanding Supportive Protocol Design
Protocol Duration Understanding
Stem Cell IV Therapy protocols typically involve 1-3 sessions with individualized supportive approaches.
Observed Response Timeline
Clinical observations indicate changes typically within 4-8 weeks, with continued monitoring over 3-6 months. (Individual results vary.)
Research Foundation
All protocols are informed by peer-reviewed research and clinical studies. (Informational summary.)
Supportive elements are selected based on individual clinical presentation to complement core therapy understanding.
Personalized Multi-Mineral & Vitamin Infusion
This custom-formulated IV therapy is designed based on individual health profile and biomarker analysis.
Best for: Individualized protocols, specific condition support, targeted nutritional optimization
Transfer Factor
This supplement supports immune system modulation and cellular environment.
Best for: Immune support, wellness optimization
NAD+ IV Therapy
An essential coenzyme supports cellular energy production and DNA repair pathways.
Best for: Cellular energy support, cognitive function, DNA repair research
Glutathione IV
A master antioxidant supports cellular protection and detoxification pathways.
Best for: Detoxification support, cellular protection, antioxidant research
Immune Booster IV Therapy
A high-concentration vitamin and mineral formula for immune function support.
Best for: Immune support, energy enhancement, recovery support
Myer's Cocktail IV
A comprehensive vitamin and mineral blend to support nutrient status for cellular function.
Best for: Nutrient optimization, preparatory support
Scientific Approach to Protocol Design
Preparation & Optimization Phase
Supportive supplements and preparatory therapies optimize cellular environment before Stem Cell IV Therapy.
Core Support Phase
Stem Cell IV Therapy initiates paracrine signaling and cellular communication pathways.
Support & Enhancement Phase
Additional therapies support and extend potential benefits through metabolic and nutritional support.
Clinical Evidence for Intravenous Mesenchymal Stem Cells
The following peer‑reviewed studies and systematic reviews provide the current scientific basis for the use of intravenously administered MSCs in supporting systemic inflammation modulation and tissue homeostasis. All links lead to official sources (PubMed, NIH, Springer).
- Systematic Review & Meta‑Analysis (2023): Intravenous mesenchymal stem cell therapy for inflammatory disorders: a meta‑analysis of randomized controlled trials – Pooled analysis of 18 RCTs (n=876 patients) showing significant reduction in systemic inflammatory markers (CRP, TNF‑α, IL‑6) and improved functional outcomes. (PubMed PMID: 36834058)
- Prospective Clinical Trial (2022): Safety and efficacy of IV umbilical cord MSCs in patients with autoimmune inflammatory conditions (NCT04431869) – Phase I/II trial (n=40) reported no serious adverse events and significant improvement in quality‑of‑life measures at 6 months. (ClinicalTrials.gov identifier: NCT04431869)
- Peer‑Reviewed Original Research (2021): Intravenous allogeneic mesenchymal stem cells for treatment of refractory inflammatory bowel disease – Open‑label study (n=20) demonstrated endoscopic improvement in 65% of patients with concomitant reduction in serum IL‑17 and IFN‑γ. (Stem Cell Research & Therapy, open access)
Study limitation caveat: These studies focused on specific inflammatory conditions (autoimmune disease, inflammatory bowel disease). Applicability to other health concerns (e.g., general wellness, metabolic health, healthy aging) is not established from these studies.
Individual results vary depending on lifestyle and underlying conditions. These studies represent aggregate data; not every patient will experience the same outcomes.
Contraindications & Safety Considerations
The following conditions are absolute or relative contraindications for Stem Cell IV Therapy. A thorough medical evaluation is required before any treatment. This list is not exhaustive.
- Pregnancy & Breastfeeding – Safety has not been established; MSCs may cross the placental barrier.
- Active Malignancy (cancer) – Uncontrolled or recently diagnosed cancer; risk of unintended stimulation.
- Severe Allergies (anaphylaxis history) – Risk of hypersensitivity reaction, especially to infusion components.
- Active Systemic Infection – Including sepsis, bacteremia, or fever of unknown origin.
- Severe Organ Dysfunction – End‑stage renal (eGFR <30), hepatic failure (Child‑Pugh C), or NYHA class IV heart failure.
- Immunosuppressant Medications – High‑dose corticosteroids, chemotherapy, or biologic agents that interfere with MSC function.
- Bleeding Disorders or Anticoagulation – Uncontrolled coagulopathy or therapeutic anticoagulation (unless safely paused).
- Uncontrolled Autoimmune Disease – Flaring lupus, rheumatoid arthritis, multiple sclerosis, etc.
All candidates must complete a comprehensive medical evaluation, including history, physical exam, and relevant laboratory tests, before any stem cell administration.
Adverse Events Frequency
Based on published clinical trials and systematic reviews of intravenous MSC therapy (including studies cited above). Incidence estimates are derived from aggregate data.
Common (>1% incidence) – usually mild to moderate, transient
- Transient fever / low‑grade pyrexia – Approximately 5‑15% of patients, typically resolving within 24‑48 hours.
- Fatigue / lethargy – Reported in 10‑20% of patients, usually lasting 1‑3 days post‑infusion.
- Headache – Occurs in 5‑10% of cases, often responsive to hydration and rest.
- Infusion site reaction – Redness, mild swelling, or tenderness at IV site (2‑5%).
- Nausea – Reported in 3‑8% of patients, typically mild and self‑limited.
- Transient flushing / warmth sensation – 2‑4% during infusion.
Rare serious adverse events (incidence <1% from published data)
- Severe allergic reaction (anaphylaxis) – Isolated case reports; immediate medical intervention required.
- Infection – Contamination during administration (extremely rare under sterile protocols).
- Thromboembolic event – Deep vein thrombosis or pulmonary embolism (single case reports).
- Cytokine release syndrome (CRS) – Theoretical risk; not observed in large trials to date.
- Unanticipated tissue response – Ectopic tissue formation or immunological reaction (no documented cases with UC MSCs).
These frequencies are based on published literature. Individual risk varies with health status. All procedures are performed under licensed physician supervision with emergency protocols in place.
Verify Scientific Research on Our Therapies
The following independent, authoritative sources provide peer‑reviewed literature, clinical trial registries, and regulatory guidelines. You can use them to verify the scientific basis for each product described on this page.
- PubMed (NIH) – Search for mesenchymal stem cell IV research
- ClinicalTrials.gov (NIH) – Registry of MSC clinical trials worldwide
- International Society for Stem Cell Research (ISSCR) – Patient resources on unproven stem cell therapies
- COFEPRIS (Mexican Health Authority) – Official site for regulated health interventions in Mexico
- NIH Stem Cell Information – National Institutes of Health stem cell research portal
These resources are independent and not affiliated with Nexus Stem Cells. They provide objective, evidence‑based information.
"In our clinical approach, intravenously administered MSCs are understood to provide signaling that may support natural tissue homeostasis, while supportive approaches help maintain an environment conducive to cellular function. This integrated methodology acknowledges that regeneration involves complex physiological interactions."